Target Details
| UniProt AC | P27361 |
|---|---|
| Gene Symbol | MAPK3 |
| Protein Name | Mitogen-activated protein kinase 3 |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF00069 (Pkinase) |
Summary
- Multi-target molecules 234
- Clinical molecules 6
- Avg pChEMBL 7.26
KEGG Pathways (120)
- AGE-RAGE signaling pathway in diabetic complications
- Acute myeloid leukemia
- Adherens junction
- Adrenergic signaling in cardiomyocytes
- Alcoholism
- Aldosterone-regulated sodium reabsorption
- Alzheimer disease
- Apelin signaling pathway
- Apoptosis
- Autophagy - animal
- Axon guidance
- B cell receptor signaling pathway
- Bladder cancer
- Breast cancer
- C-type lectin receptor signaling pathway
- Cadherin signaling
- Cellular senescence
- Central carbon metabolism in cancer
- Chagas disease
- Chemical carcinogenesis - reactive oxygen species
- Chemical carcinogenesis - receptor activation
- Chemokine signaling pathway
- Choline metabolism in cancer
- Cholinergic synapse
- Chronic myeloid leukemia
- Circadian entrainment
- Colorectal cancer
- Coronavirus disease - COVID-19
- Cushing syndrome
- EGFR tyrosine kinase inhibitor resistance
- Efferocytosis
- Endocrine resistance
- Endometrial cancer
- ErbB signaling pathway
- Estrogen signaling pathway
- Fc epsilon RI signaling pathway
- Fc gamma R-mediated phagocytosis
- Focal adhesion
- FoxO signaling pathway
- Gap junction
- Gastric cancer
- Glioma
- Glutamatergic synapse
- GnRH secretion
- GnRH signaling pathway
- Growth hormone synthesis, secretion and action
- HIF-1 signaling pathway
- Hepatitis B
- Hepatitis C
- Hepatocellular carcinoma
- Human T-cell leukemia virus 1 infection
- Human cytomegalovirus infection
- Human immunodeficiency virus 1 infection
- Human papillomavirus infection
- IL-17 signaling pathway
- IgSF CAM signaling
- Influenza A
- Insulin signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Leishmaniasis
- Lipid and atherosclerosis
- Long-term depression
- Long-term potentiation
- MAPK signaling pathway
- Melanogenesis
- Melanoma
- MicroRNAs in cancer
- NOD-like receptor signaling pathway
- Natural killer cell mediated cytotoxicity
- Neurotrophin signaling pathway
- Neutrophil extracellular trap formation
- Non-small cell lung cancer
- Oocyte meiosis
- Osteoclast differentiation
- Oxytocin signaling pathway
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Parathyroid hormone synthesis, secretion and action
- Pathogenic Escherichia coli infection
- Pathways in cancer
- Pathways of neurodegeneration - multiple diseases
- Pertussis
- Phospholipase D signaling pathway
- Platelet activation
- Platinum drug resistance
- Prion disease
- Progesterone-mediated oocyte maturation
- Prolactin signaling pathway
- Prostate cancer
- Proteoglycans in cancer
- Rap1 signaling pathway
- Ras signaling pathway
- Regulation of actin cytoskeleton
- Relaxin signaling pathway
- Renal cell carcinoma
- Retrograde endocannabinoid signaling
- Salmonella infection
- Serotonergic synapse
- Shigellosis
- Signaling pathways regulating pluripotency of stem cells
- Sphingolipid signaling pathway
- T cell receptor signaling pathway
- TGF-beta signaling pathway
- TNF signaling pathway
- Th1 and Th2 cell differentiation
- Th17 cell differentiation
- Thyroid cancer
- Thyroid hormone signaling pathway
- Toll-like receptor signaling pathway
- Toxoplasmosis
- Tuberculosis
- Type II diabetes mellitus
- VEGF signaling pathway
- Vascular smooth muscle contraction
- Viral carcinogenesis
- Yersinia infection
- cAMP signaling pathway
- cGMP-PKG signaling pathway
- mTOR signaling pathway
Active Molecules (234)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
MIISUCGGVANLKC
|
6.3 | IC50 | 2 | — | |
IBGLGMOPHJQDJB
|
6.3 | IC50 | 8 | Yes | |
IBGLGMOPHJQDJB
|
6.3 | IC50 | 5 | — | |
KFQWHXCKZQIVTI
|
6.3 | IC50 | 4 | — | |
MJHCUHULQWWLSQ
|
6.3 | IC50 | 3 | — | |
YCDLYDFEISVJID
|
6.3 | IC50 | 2 | — | |
RAYLADSIJRNUEN
|
6.3 | IC50 | 2 | — | |
VUXHDBFZTVRSRN
|
6.2 | IC50 | 3 | — | |
FRQZXBWIZAWOLU
|
6.2 | IC50 | 3 | — | |
NOOAKNBOIMAWSA
|
6.2 | IC50 | 4 | — | |
GDENZVFEXVRWNZ
|
6.2 | IC50 | 2 | — | |
KIGLGOKRWJXVTH
|
6.2 | IC50 | 2 | — | |
SEYQXKIRSCBUBZ
|
6.2 | IC50 | 3 | — | |
PRWOTQUYNWSNFC
|
6.2 | IC50 | 4 | — | |
VNDPDOBDSCDEBX
|
6.2 | IC50 | 4 | — | |
MQSCGRDOQBVIMP
|
6.2 | IC50 | 5 | — | |
PKRRWXXVUMOSGN
|
6.1 | IC50 | 2 | — | |
LSGWJMLNFPIPPC
|
6.1 | IC50 | 4 | Yes | |
OPHYBUHBYGTOAL
|
6.1 | IC50 | 3 | — | |
IPILYXRPIMXNGK
|
6.1 | IC50 | 3 | — | |
JXKNNYQQOGCFRS
|
6.1 | IC50 | 4 | — | |
SFVJWENBPAOGME
|
6.1 | IC50 | 2 | — | |
VPUIGWUVOAHTDT
|
6.1 | IC50 | 3 | — | |
PRQMKPLDKYLQOM
|
6.1 | IC50 | 2 | — | |
QEHQYWPWDIMKOU
|
6.0 | IC50 | 4 | — | |
YDLFKTCJWVZYQW
|
6.0 | IC50 | 2 | — | |
ZDSWMSRFTNIEJV
|
6.0 | IC50 | 2 | — | |
ARIOBGGRZJITQX
|
6.0 | IC50 | 24 | — | |
IVVSBEQDCAZLFY
|
6.0 | IC50 | 333 | — | |
KHVVJKLNKLQLJZ
|
6.0 | IC50 | 288 | — | |
MAHFVAHPQSLLJF
|
6.0 | IC50 | 288 | — | |
PGWKGYOSINQMSU
|
6.0 | IC50 | 3 | — | |
QUUCFUYEUOFYMK
|
6.0 | IC50 | 2 | — | |
RMZKUOVRTWVBDH
|
6.0 | IC50 | 3 | — |